Therapeutic biomarker differences between MSI-H and MSS colorectal cancers


Zoran Gatalica, Namrata Vijayvergia, Semir Vranic, Joanne Xiu, 1Sandeep K. Reddy, 4Carrie L. Snyder, 4Henry T. Lynch, 2Wafik S. El-Deiry


Approximately 15% of colorectal cancers (CRC) display high level of microsatellite instability (MSI-H) due to either hereditary predisposition (Lynch syndrome, LS) or somatic hypermethylation of MLH1. They carry a significantly different prognosis and responses to treatments compared with microsatellite stable (MSS) or low microsatellite instability (MSI-L) CRC. We
investigated therapeutically important biomarkers, which may underlie different treatment options for CRC.

Download Publication